BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma

  September 30, 2024

   · 

  27 min read
• Press Releases

  Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

  September 30, 2024

   · 

  12 min read
• Press Releases

  Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

  September 30, 2024

   · 

  24 min read
• Press Releases

  Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease

  September 30, 2024

   · 

  13 min read
• Press Releases

  Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company

  September 30, 2024

   · 

  2 min read
• Press Releases

  Mitsubishi Tanabe Pharma America to Highlight Data on Investigational ND0612 at the 2024 International Congress of Parkinson’s Disease and Movement Disorders

  September 30, 2024

   · 

  5 min read
• Press Releases

  DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

  September 30, 2024

   · 

  12 min read
• Press Releases

  PacBio Grants Equity Incentive Award to New Employee - September 27, 2024

  September 30, 2024

   · 

  2 min read
• Press Releases

  CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

  September 30, 2024

   · 

  29 min read
• Press Releases

  FDA Roundup: September 27, 2024

  September 30, 2024

   · 

  8 min read